CN117042769A - 作为布鲁顿酪氨酸激酶(btk)降解剂的取代的吡咯并嘧啶和吡唑并嘧啶 - Google Patents

作为布鲁顿酪氨酸激酶(btk)降解剂的取代的吡咯并嘧啶和吡唑并嘧啶 Download PDF

Info

Publication number
CN117042769A
CN117042769A CN202280022626.5A CN202280022626A CN117042769A CN 117042769 A CN117042769 A CN 117042769A CN 202280022626 A CN202280022626 A CN 202280022626A CN 117042769 A CN117042769 A CN 117042769A
Authority
CN
China
Prior art keywords
pyrimidin
amino
piperazin
dioxopiperidin
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280022626.5A
Other languages
English (en)
Chinese (zh)
Inventor
Y·钱
W·何
R·罗
J·苏
H·张
K·刘
J·范
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accutar Biotechnology Inc
Original Assignee
Accutar Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accutar Biotechnology Inc filed Critical Accutar Biotechnology Inc
Publication of CN117042769A publication Critical patent/CN117042769A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280022626.5A 2021-02-03 2022-02-02 作为布鲁顿酪氨酸激酶(btk)降解剂的取代的吡咯并嘧啶和吡唑并嘧啶 Pending CN117042769A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163145126P 2021-02-03 2021-02-03
US63/145,126 2021-02-03
PCT/US2022/014830 WO2022169798A2 (en) 2021-02-03 2022-02-02 Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders

Publications (1)

Publication Number Publication Date
CN117042769A true CN117042769A (zh) 2023-11-10

Family

ID=80447078

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280022626.5A Pending CN117042769A (zh) 2021-02-03 2022-02-02 作为布鲁顿酪氨酸激酶(btk)降解剂的取代的吡咯并嘧啶和吡唑并嘧啶

Country Status (11)

Country Link
US (2) US20240132502A1 (https=)
EP (2) EP4501327A3 (https=)
JP (1) JP2024505558A (https=)
KR (1) KR20230142539A (https=)
CN (1) CN117042769A (https=)
CA (1) CA3209082A1 (https=)
DK (1) DK4039688T3 (https=)
ES (1) ES3010513T3 (https=)
FI (1) FI4039688T3 (https=)
MX (1) MX2023008865A (https=)
WO (1) WO2022169798A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025179653A1 (en) * 2024-02-26 2025-09-04 China Pharmaceutical University Non-ubiquitin target protein degrader nutac and uses thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202317099A (zh) * 2020-09-10 2023-05-01 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN118434717A (zh) * 2021-12-20 2024-08-02 西格马-奥尔德里奇有限责任公司 化学接头
WO2024169871A1 (zh) * 2023-02-17 2024-08-22 江苏威凯尔医药科技有限公司 Btk抑制剂及其用途
WO2024244888A1 (zh) * 2023-05-26 2024-12-05 广东弘烨医药科技有限公司 9元杂芳基化合物、含其的药物组合物及其制备方法和应用
AU2024298923A1 (en) 2023-07-25 2026-01-22 Monte Rosa Therapeutics Ag Substituted piperidinediones for targeted protein degradation
WO2026040951A1 (zh) * 2024-08-19 2026-02-26 深圳市塔吉瑞生物医药股份有限公司 靶向btk蛋白降解靶向嵌合体类化合物及其组合物及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108431007A (zh) * 2015-09-16 2018-08-21 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
WO2020239103A1 (zh) * 2019-05-31 2020-12-03 四川海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN106146511A (zh) * 2015-04-03 2016-11-23 安润医药科技（苏州）有限公司 吡唑并嘧啶衍生物、制备方法、药物组合物及用途
ES2965081T3 (es) * 2016-07-07 2024-04-11 Daewoong Pharmaceutical Co Ltd Derivados 4-aminopirazolo[3,4-d]pirimidinil-azabiciclo y composición farmacéutica que comprende dichos derivados
TW201811795A (zh) * 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
EP3765026A4 (en) * 2018-03-10 2021-12-22 Yale University BTK PROTEOLYSIS MODULATORS AND METHODS FOR USE
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
CN112812100B (zh) * 2019-11-18 2022-04-05 四川海思科制药有限公司 一种具有降解btk激酶的化合物及其制备方法和药学上的应用
CN112979656A (zh) * 2019-12-12 2021-06-18 上海美志医药科技有限公司 一类靶向降解btk蛋白的化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108431007A (zh) * 2015-09-16 2018-08-21 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
WO2020239103A1 (zh) * 2019-05-31 2020-12-03 四川海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025179653A1 (en) * 2024-02-26 2025-09-04 China Pharmaceutical University Non-ubiquitin target protein degrader nutac and uses thereof

Also Published As

Publication number Publication date
US20220259207A1 (en) 2022-08-18
ES3010513T3 (en) 2025-04-03
EP4039688B1 (en) 2024-10-09
DK4039688T3 (da) 2025-01-02
EP4039688A3 (en) 2022-11-23
WO2022169798A2 (en) 2022-08-11
JP2024505558A (ja) 2024-02-06
EP4039688A2 (en) 2022-08-10
CA3209082A1 (en) 2022-08-11
MX2023008865A (es) 2023-08-31
FI4039688T3 (fi) 2024-12-19
EP4501327A3 (en) 2025-10-15
KR20230142539A (ko) 2023-10-11
US20240132502A1 (en) 2024-04-25
US11530222B2 (en) 2022-12-20
WO2022169798A3 (en) 2022-09-22
EP4501327A2 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
CN117042769A (zh) 作为布鲁顿酪氨酸激酶(btk)降解剂的取代的吡咯并嘧啶和吡唑并嘧啶
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
JP7840517B2 (ja) 二環式複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
TWI657076B (zh) 經取代磺醯胺化合物
TWI804003B (zh) Tlr7/8拮抗劑及其用途
CN109563075B (zh) Tlr7/8拮抗剂及其用途
CN104583196B (zh) 1,4-二取代的哒嗪类似物以及治疗与smn缺乏相关的病症的方法
CN105837576B (zh) Btk抑制剂
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
WO2020182159A1 (zh) Jak激酶抑制剂及其制备方法和在医药领域的应用
TW201722933A (zh) 苯內醯胺化合物
WO2015165279A1 (zh) 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2022194269A1 (zh) 新型egfr降解剂
CN108137547A (zh) 可用作TNFα调节剂的杂环化合物
TW201443023A (zh) 作爲ｒｏｃｋ抑制劑之酞□酮及異喹啉酮
TW201522342A (zh) 用於治療寄生蟲疾病之化合物及組合物
CN109641897B (zh) Bcl-2选择性抑制剂及其制备和用途
WO2021139595A1 (zh) RORγt抑制剂及其制备方法和用途
EP4034114A1 (en) Novel ureas having androgen receptor degradation activity and uses thereof
TW201617343A (zh) 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
WO2022199599A1 (zh) 丙烯酰基取代的化合物、包含其的药物组合物及其用途
WO2022048631A1 (zh) 一种具有抗肿瘤活性的化合物及其用途
CN108884093A (zh) 6,7,8,9-四氢-5H-吡啶并[2,3-d]氮杂*多巴胺D3配体
WO2022237858A1 (zh) 一种具有抗肿瘤活性的化合物及其用途
CN112313220B (zh) Pd-l1拮抗剂化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination